01 / DESIGN
What was studied?
The phase 2 trial randomized 338 adults with obesity or overweight and a related condition to retatrutide study groups or placebo over 48 weeks.
02 / FINDINGS
What did the researchers report?
Retatrutide groups showed greater average weight reduction than placebo. Gastrointestinal adverse events and increases in heart rate were reported, making safety observations part of the interpretation.
03 / LIMITS
How should it be interpreted?
Phase 2 results are not a substitute for larger and longer studies. This paper alone cannot establish long-term safety, regulatory status or equivalence between the tested formulation and research-supply products.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.